Project Notice |
|
| PNR | 19046 |
| Project Name | Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma |
| Project Detail | Melanoma is the most aggressive form of skin cancer resistant to all standard therapies. Currently, the established treatment of metastatic melanoma includes dacarbazine (DTIC) administration associated with response rates of between 10-20% with severe side effects during treatment. Recently, the BRAF inhibitors (vemurafenib and dabrafenib) and the MEK inhibitor (trametinib) were approved for the treatment of melanoma patients with mutated BRAF (about 50% of patients) while … |
| Funded By | European union |
| Sector | Health and Medical |
| Country | Portugal , Western Europe |
| Project Value | EUR 160,636 |
Contact Information |
|
| Company Name | UNIVERSIDADE DO ALGARVE |
| Address | CAMPUS DE PENHA 8005 139 FARO Portugal |
| Web Site | https://cordis.europa.eu/project/rcn/208947_en.html |
